Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") announced that they have ent...
GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, announced the achievement of t...
ASTRIDE trial for first-line ES-SCLC demonstrated favorable median overall survival in serplulimab with chemotherapy versus atezo...
HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapie...
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted...
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction,...
Advanced Clinical, a global clinical research organization (CRO) providing full-service clinical development, functional service provider (FSP) solutions a...
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerativ...
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-nega...
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, announced results from an independent evaluation of myStage Dx, its CE-IVD...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for t...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced that it has received full regulato...
© 2026 Biopharma Boardroom. All Rights Reserved.
